Physician profile
Sagar Patel
NPI 1528327210
$388,519.29
in general payments reported to CMS, 2019-2025
26 companies · $198K in 2025
The $198K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $2,215 · 2021: $5,231 · 2022: $19K · 2023: $85K · 2024: $80K · 2025: $198K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $259K · Consulting Fee: $50K · Travel and Lodging: $43K · Food and Beverage: $7,502 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $258,718.50 |
| Consulting Fee | $49,692.00 |
| Travel and Lodging | $43,125.92 |
| Food and Beverage | $7,502.22 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,195.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $175,406.71 | 2023-2025 | |
| Kite Pharma, INC. | $120,934.89 | 2020-2025 | Yescarta |
| Incyte Corporation | $47,362.11 | 2021-2025 | Jakafi, Jakafi, Niktimvo |
| Genzyme Corporation | $10,335.98 | 2025 | |
| Cti Biopharma Corp. | $10,195.00 | 2023 | Vonjo |
| E.R. Squibb & Sons, L.L.C. | $6,539.50 | 2023-2025 | |
| Stemline Therapeutics INC. | $5,460.00 | 2025 | Elzonris |
| Sobi, INC | $4,324.05 | 2025 | |
| Medexus Pharma, INC. | $2,380.59 | 2022-2024 | |
| Gamida Cell INC. | $2,191.07 | 2023-2024 | Omisirge |
| Celgene Corporation | $705.37 | 2023-2024 | Onureg, Abecma |
| Mckesson Drug Company LLC | $610.00 | 2023 | |
| Zoll Medical Corporation | $520.00 | 2024 | Defibrillator |
| Abbvie INC. | $280.93 | 2022 | |
| Jazz Pharmaceuticals INC. | $241.53 | 2022-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $205.39 | 2021-2024 | Clonoseq |
| Alexion Pharmaceuticals, INC. | $200.00 | 2022 | |
| Amgen INC. | $164.99 | 2019 | |
| Pharming Healthcare, INC. | $138.64 | 2023 | Ruconest |
| Kadmon Pharmaceuticals LLC | $133.48 | 2021 | |
| Karyopharm Therapeutics INC. | $87.35 | 2022 | |
| Lilly USA, LLC | $39.36 | 2024 | Jaypirca |
| Siemens Medical Solutions USA, INC. | $32.40 | 2025 | Symbia.Net |
| Menarini Silicon Biosystems, INC. | $22.83 | 2023 | Cellsearch |
| Rigel Pharmaceuticals, INC. | $7.12 | 2024 | Tavalisse, Rezlidhia |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sagar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.